TEL AVIV, Israel, Cellect Biomed Ltd. a developer of innovative technology that
enables the functional selection of stem cells, announced today that it
has been granted a patent for its technology platform for cell
selection from the Canadian Intellectual Property Office.
The
patent protects the usage of apoptosis-inducing materials for the
destruction of cells that inhibit the receipt of bone marrow grafts.
With patents already issued in the United States, Europe, India and
Israel, this Canadian patent expands Cellect’s already formidable
intellectual property estate.
Dr. Shai Yarkoni,
the Company's CEO, noted: "Our business model is based not only on our
internal development of new products for various medical needs, but also
on collaborations and out-licenses of our technology to companies and
research institutions in the field. Accordingly, as awareness and
acceptance of our ground-breaking technology platform continues to grow
amongst physicians, patients, researchers and potential partners, it is
vital this opportunity is well protected.”
Cellect
is making final preparations for the planned launch of its first
clinical trial in leukemia patients, following the receipt of IRB
approval from the Rambam Hospital. The trial will be conducted in the
bone marrow transplantation (“BMT”) unit and led by Clinical Assistant
Professor Zila Zuckerman, the Director of the unit, subject to the
approval of the Israeli Ministry of Health.
The
trial is a first of its kind in leukemia patients in need of bone marrow
transplantation. In the clinical trial, the BMT process will be
performed at the Rambam Hospital in leukemia patients using Cellect's
cell selection technology, "Cellect Inside".
No comments:
Post a Comment